Boston Scientific Corporation
NYSE•BSX
CEO: Mr. Michael F. Mahoney
セクター: Healthcare
業種: Medical - Devices
上場日: 1992-05-19
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
連絡先情報
300 Boston Scientific Way, Marlborough, MA, 01752-1234, United States
508-683-4000
時価総額
$105.65B
PER (TTM)
36.5
32.6
配当利回り
--
52週高値
$109.50
52週安値
$67.56
52週レンジ
順位35Top 29.9%
4.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$5.29B+0.00%
直近4四半期の推移
EPS
$0.45+0.00%
直近4四半期の推移
フリーCF
$1.01B+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Strong 2025 Sales Growth Reported net sales reached $20.07B USD in 2025, showing 19.9% growth over 2024 results.
Net Income Jumps Significantly Reported net income attributable to stockholders was $2.90B USD, increasing 56.4% compared to the prior year.
Organic Growth Remains Robust Organic net sales growth reached 15.8% in 2025, primarily driven by strong commercial execution in Electrophysiology.
Adjusted EPS Rises Adjusted diluted EPS reached $3.06 USD, demonstrating 21.9% operational performance improvement versus 2024.
リスク要因
Intense Market Competition Highly competitive medical device markets face pressure from large rivals, emerging low-cost offerings, and rapid technology changes.
Pricing and Market Size Declines Potential declines in market size, average selling prices, and procedure volumes could adversely affect financial results.
Geopolitical Supply Chain Risks Global conflicts and trade tensions create uncertainty impacting supply chains, increasing costs, and disrupting operations.
Regulatory Scrutiny Increases Increasing complexity of global regulations, including MDR and data privacy laws, raises compliance costs and risks.
見通し
Strategic Growth Imperatives Strategic imperatives focus on strengthening category leadership and expanding presence into high-growth adjacencies across global markets.
Major Penumbra Acquisition Definitive agreement signed to acquire Penumbra for approximately $14.50B USD, expected to close during 2026.
R&D Investment Critical Continued investment in R&D supports development of next-generation technologies for future profitable sales growth.
Liquidity Position Strong Existing cash, operational cash flow, and credit facilities provide sufficient funding for operations and foreseeable future needs.
同業比較
売上高 (TTM)
$397.96B
$75.60B
$62.58B
粗利益率 (最新四半期)
86.8%
81.9%
74.5%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| AMGN | $194.67B | 25.2 | 96.7% | 60.3% |
| ABT | $192.38B | 29.6 | 12.9% | 17.4% |
| GILD | $179.26B | 21.1 | 41.0% | 41.7% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.3%
緩やかな成長
4四半期純利益CAGR
-0.3%
収益性の安定
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年4月21日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし